公开(公告)号：US20210347905A1

公开(公告)日：2021-11-11

申请号：US17127629

申请日：2020-12-18

Applicant: Amgen Inc.

Inventor： Xin YU ,  Jackson EGEN ,  Fernando GARCES ,  Shunsuke TAKENAKA ,  AeRyon KIM ,  Deepali SAWANT

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/04

Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

公开(公告)号：US20240150481A1

公开(公告)日：2024-05-09

申请号：US18417708

申请日：2024-01-19

Applicant: Amgen Inc.

Inventor： Xin YU ,  Jackson EGEN ,  Fernando GARCES ,  Shunsuke TAKENAKA ,  AeRyon KIM ,  Deepali SAWANT

IPC: C07K16/28 ,  A61P35/04 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61P35/04 ,  C07K16/30 ,  A61K2039/505

Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

公开(公告)号：US20210301020A1

公开(公告)日：2021-09-30

申请号：US17262339

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： Xin YU ,  Wenjun OUYANG ,  Chi-Ming Kevin LI ,  Jackson Graeme EGEN ,  Oh Kyu YOON ,  Ian Halsey DRIVER ,  Shunsuke TAKENAKA ,  Christy Ann THOMSON ,  Hongyu WANG

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.